UK-based Global Clinical Research Organisation (CRO), ClinTec International has unveiled a significant expansion into the US marketplace, with the launch of its New York office and the appointment of Susan Pavone, Associate Director of US Business Operations.
“Developing an internal CRO for Pfizer, Inc. was much like starting an independent business”
To date, ClinTec has grown its business operations organically from its European base and expanded into over 40-countries worldwide - with its US operations centred on servicing major international companies on global projects by partnering with US CROs that had no or limited international presence.
In 2009, ClinTec increased global sales revenues by 45%, opening new offices in 17 different countries. Today's announcement, establishes a solid foothold for the company in the lucrative US market. The expansion of US based operations through the launch of American headquarters, together with Susan Pavone's appointment, will enable ClinTec to offer prospective US clients the chance to access global clinical research capabilities through a single partner.
In the current economic climate, US life science and pharmaceutical companies are struggling to find medium sized global CROs capable of facilitating global clinical research needs. ClinTec has implemented a differentiated solution to mid-market competitors which combines all developed and emerging markets into a single global research platform.
President & CEO of ClinTec International, Dr Rabinder Buttar, commented: "We have established a strong presence in the international marketplace by placing expert clinical research staff in all key emerging, and established markets. The pharmaceutical industry is currently searching for new ways of working and delivering global solutions. ClinTec's ability to harness global strength, coupled with local, on the ground expertise, will be of great value to US pharmaceutical companies. Our new Associate Director of (US) Operations, Susan Pavone, has extensive knowledge of international clinical research and the new US facilities will prove an invaluable asset to American companies looking to tap into our globalised resources and expertise."